Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Diseases
Parkinson's Disease
Multiple Sclerosis and Related Disorders
Headache
Amyotrophic Lateral Sclerosis
Epilepsy
Sleep Disorders
Stroke
Neuromuscular Disorders
Movement Disorders
View all Diseases
Topics
Biology
Diagnostics
Trial Updates
Treatment
Prevention
Surgery
Imaging
Genetics
COVID-19
View all Topics
Conferences
EAN 2022
ESOC 2022
AAN 2022
CONy 2022
AD/PD 2022
World Sleep 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Ocrelizumab
1:39
Progressive MS treatment – what is next?
Giancarlo Comi
• 23 Mar 2022
3:14
Using DMTs beyond patients with active MS
Xavier Montalban
• 29 Mar 2022
1:30
Differential efficacy of DMTs in patients with active and inactive MS
Xavier Montalban
• 29 Mar 2022
6:03
Changes in the MS treatment landscape over the last 2 years
Abhijit Chaudhuri
• 22 Mar 2022
5:33
Real-world studies of CGRP monoclonal antibodies and gepants for migraine
Chia-Chun Chiang
• 3 Apr 2022
1:51
Selecting treatment options for NMOSD
Michael Levy
• 3 Apr 2022
8:46
Deep learning can predict treatment response in patients with progressive MS
Jean-Pierre Falet
• 22 Mar 2022
3:15
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs
Virginia Meca-Lallana
• 28 Feb 2022
3:33
Study of real-world evidence in patients with PMS and RMS treated with ocrelizumab
Virginia Meca-Lallana
• 28 Feb 2022
2:52
Impact of ocrelizumab disruption on RRMS
Kelly Cotchett
• 25 Feb 2022
2:07
Characterizing real-world outcomes among COVID-19 vaccinated patients with MS
Namita Tundia
• 25 Feb 2022
1:57
COVID booster vaccines do not lead to humoral responses in patients with MS treated with DMTs
Celia Oreja-Guevara
• 24 Feb 2022
7:33
Comparing exit strategies in natalizumab-responders at high risk for PML
Emanuele D'Amico
• 30 Sep 2021
7:22
COVID-19 vaccination in patients with MS
Maria Pia Sormani
• 13 Oct 2021
4:37
Delaying MS treatment to boost COVID-19 vaccination effects
Anat Achiron
• 12 Oct 2021
1:49
COVID-19 cases in MS patients receiving IV therapy
Celia Oreja-Guevara
• 14 Oct 2021
1
2
3
Next